Though, in the current study, DFS was not determined, we found that PD-L1 immunoexpression at a cut-off of ≥50% was significantly associated with the parameters, which are associated with a poor clinical outcome like lymph nodal metastasis and tumour necrosis. The gene discussed is CD274; the disease is neoplasm.